SIMCERE PHARMAC Earnings Per Share vs. Number Of Employees

S2P Stock  EUR 0.85  0.03  3.41%   
Based on the measurements of profitability obtained from SIMCERE PHARMAC's financial statements, SIMCERE PHARMAC GRP may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess SIMCERE PHARMAC's ability to earn profits and add value for shareholders.
For SIMCERE PHARMAC profitability analysis, we use financial ratios and fundamental drivers that measure the ability of SIMCERE PHARMAC to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well SIMCERE PHARMAC GRP utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between SIMCERE PHARMAC's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of SIMCERE PHARMAC GRP over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between SIMCERE PHARMAC's value and its price as these two are different measures arrived at by different means. Investors typically determine if SIMCERE PHARMAC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SIMCERE PHARMAC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

SIMCERE PHARMAC GRP Number Of Employees vs. Earnings Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining SIMCERE PHARMAC's current stock value. Our valuation model uses many indicators to compare SIMCERE PHARMAC value to that of its competitors to determine the firm's financial worth.
SIMCERE PHARMAC GRP is currently regarded as top stock in earnings per share category among its peers. It also is currently regarded as top stock in number of employees category among its peers creating about  130,840  of Number Of Employees per Earnings Per Share. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SIMCERE PHARMAC's earnings, one of the primary drivers of an investment's value.

SIMCERE Number Of Employees vs. Earnings Per Share

Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

SIMCERE PHARMAC

Earnings per Share

 = 

Earnings

Average Shares

 = 
0.05 X
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.

SIMCERE PHARMAC

Number of Employees

 = 

Full Time

+

Part Time

 = 
6.54 K
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.

SIMCERE Number Of Employees vs Competition

SIMCERE PHARMAC GRP is currently regarded as top stock in number of employees category among its peers. The total workforce of Drug Manufacturers-Specialty & Generic industry is at this time estimated at about 96,665. SIMCERE PHARMAC holds roughly 6,542 in number of employees claiming about 7% of equities under Drug Manufacturers-Specialty & Generic industry.

SIMCERE Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on SIMCERE PHARMAC. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of SIMCERE PHARMAC position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the SIMCERE PHARMAC's important profitability drivers and their relationship over time.

Use SIMCERE PHARMAC in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SIMCERE PHARMAC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SIMCERE PHARMAC will appreciate offsetting losses from the drop in the long position's value.

SIMCERE PHARMAC Pair Trading

SIMCERE PHARMAC GRP Pair Trading Analysis

The ability to find closely correlated positions to SIMCERE PHARMAC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SIMCERE PHARMAC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SIMCERE PHARMAC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SIMCERE PHARMAC GRP to buy it.
The correlation of SIMCERE PHARMAC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SIMCERE PHARMAC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SIMCERE PHARMAC GRP moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SIMCERE PHARMAC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your SIMCERE PHARMAC position

In addition to having SIMCERE PHARMAC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Retail Thematic Idea Now

Retail
Retail Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Retail theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Retail Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in SIMCERE Stock

To fully project SIMCERE PHARMAC's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of SIMCERE PHARMAC GRP at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include SIMCERE PHARMAC's income statement, its balance sheet, and the statement of cash flows.
Potential SIMCERE PHARMAC investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although SIMCERE PHARMAC investors may work on each financial statement separately, they are all related. The changes in SIMCERE PHARMAC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on SIMCERE PHARMAC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.